Collaborative Connector News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Collaborative connector. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Collaborative Connector Today - Breaking & Trending Today

Molecule holds promise to reprogram white blood cells for better cancer treatment


 E-Mail
IMAGE: Pictured L-R: Caitlin Brandle, research assistant, Dr. Gang Zhou, Timothy Kim, undergraduate student, Nada S. Aboelella, PhD, graduate student, Dr. Zhi-Chun Ding, assistant professor
view more 
Credit: Kim Ratliff, AU photographer
Cancer immunotherapy using designer immune cells has revolutionized cancer treatment in recent years. In this type of therapy, T cells, a type of white blood cell, are collected from a patient s blood and subjected to genetic engineering to produce T cells carrying a synthetic molecule termed chimeric antigen receptor (CAR) that is designed to enable T cells to recognize and destroy cancer cells. Then these genetically modified CAR T cells are expanded to large quantity and infused back to the patient. ....

United States , Huidong Shi , National Cancer Institute , Augusta University , Outpatient Services , College Of Georgia , Georgia Cancer Center , Department Of Medicine , Gang Zhou , Medical College , Cancer Immunology , Georgia Cancer , Science Immunology , Storey Research Building , Collaborative Connector , Laney Walker , Zhi Chun Ding , National Cancer , ஒன்றுபட்டது மாநிலங்களில் , தேசிய புற்றுநோய் நிறுவனம் , அகஸ்டா பல்கலைக்கழகம் , ஔட்‌ப்யாஶஂட் சேவைகள் , கல்லூரி ஆஃப் ஜார்ஜியா , ஜார்ஜியா புற்றுநோய் மையம் , துறை ஆஃப் மருந்து , கும்பல் ஜூ ,

Study shows how STAT5 optimizes function of CD4+ T cells to drive antitumor immunity


Study shows how STAT5 optimizes function of CD4+ T cells to drive antitumor immunity
Cancer immunotherapy using designer immune cells has revolutionized cancer treatment in recent years. In this type of therapy, T cells, a type of white blood cell, are collected from a patient s blood and subjected to genetic engineering to produce T cells carrying a synthetic molecule termed chimeric antigen receptor (CAR) that is designed to enable T cells to recognize and destroy cancer cells.
Then these genetically modified CAR T cells are expanded to large quantities and infused back to the patient.
CAR T cell-based immunotherapies have seen remarkable outcomes in some patients with certain types of cancer, but more work is needed to improve the persistence and function of CAR T cells so that more patients can benefit from this type of therapy. ....

United States , Emily Henderson , Augusta University , Outpatient Services , College Of Georgia , Georgia Cancer Center , Department Of Medicine , Gang Zhou , Medical College , Cancer Immunology , Georgia Cancer , Science Immunology , Storey Research Building , Collaborative Connector , Laney Walker , Faculty Member , ஒன்றுபட்டது மாநிலங்களில் , எமிலி ஹென்டர்சன் , அகஸ்டா பல்கலைக்கழகம் , ஔட்‌ப்யாஶஂட் சேவைகள் , கல்லூரி ஆஃப் ஜார்ஜியா , ஜார்ஜியா புற்றுநோய் மையம் , துறை ஆஃப் மருந்து , கும்பல் ஜூ , மருத்துவ கல்லூரி , புற்றுநோய் நோயெதிர்ப்பு ,